Hubei Renfu Chengtian Pharmaceutical Co., Ltd.

To preliminarily evaluate the efficacy and safety of HZ-J001 cream of different strengths in the treatment of non-segmental vitiligo; to evaluate the systemic exposure of HZ-J001 cream in patients with non-segmental vitiligo

Primary objective: To evaluate the safety and tolerability of HZ-J001 cream in healthy adult subjects, and to provide a safety basis for determining the dosage and area of administration used in later trials. Secondary objective: To evaluate the systemic exposure level and pharmacokinetic characteristics of 1.0%, 1.5%, and 2.0% HZ-J001 cream in healthy adult subjects after single and multiple topical skin administration.

The desonide cream produced by Hubei Renfu Chengtian Pharmaceutical Co., Ltd. was used as the test preparation, and the desonide cream (0.05%, Perrigo®) certified by Perrigo New York Inc. was used as the reference preparation. The in vivo exposure ratio of the test preparation and the reference preparation after local administration was studied to evaluate the safety of the test preparation.